IVIG

Although a single IVIG dose of 25 g was effective in most cases, for some strains repeated doses were necessary to achieve a significant reduction in superantigenic responses.

Both intravenous immunoglobulin and subcutaneous immunoglobulin are effective in treating myasthenia gravis.

Providers must account for important considerations when choosing the appropriate therapy for each patient based on their specific needs.

The trial’s main goal is to compare the health status of participants in the combination treatment group with participants in the remdesivir-only group on day 7.

Although researchers still hope to learn what protection immunoglobulin G antibodies offer against re-infection, this study could have broad implications in the development of a COVID-19 vaccine.

Intravenous Immunoglobulin helps to improve hypoxia, which can reduce the need for mechanical ventilation.

When treating these diseases, immunoglobulin is effective because of its ability to be used by the immune system to neutralize pathogens, such as pathogenic bacteria, fungi, and viruses.

Myasthenia gravis is most commonly caused by binding of immunoglobulin G (IgG) antibodies to the postsynaptic acetylcholine receptor (AChR), although other receptors may also be involved.

A study found that intravenous immune globulin dosing optimization through alternative dosing weights represents a significant source of waste reduction and cost reduction.

In this study, researchers wanted to evaluate the frequency of reduced immunoglobulin concentrations and its association with immunotherapy and disease course in 2 independent cohorts with multiple sclerosis.

Carefully implemented order sets may encourage evidence-based or institution-specific care though the influence of provider behavior.

Five-day adjuvant IVIG therapy found to significantly reduce viral load in an immunocompromised patient with severe varicella.

The case study included a 45-year-old man diagnosed with stage 3 multiple myeloma who was treated with bortezomib and dexamethasone.

The study authors wanted to determine the prevalence and clinical significances of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.

IVIG found to have a good safety profile in pediatric patients, with low risk of severe adverse drug reactions.

Study is the first to identify the presence of anti-citrullinated protein autoantibodies in human tear fluid as well as discover the new eye drop treatment.

Study seeks to determine the prevalence and clinical significance of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.

Metabolic activity in the immune cells of patients with primary immunodeficiency was used as a biomarker due to cellular metabolism, which serves as a key regulator in immune cells.

Debilitating and degenerative, chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease affecting 1.6 per 100,000 Americans annually.

Trial finds that the addition of anti-HIV immune globulin to standard of care patients with influenza B had a significant virological benefit.

In a Pharmacy Times® Continuing Education Supplement, Leslie J. Vaughan, BS, RPH, examined cost and health care utilization in patients using immunoglobulin agents.

Subcutaneous immunoglobin has increased treatment options for patients with several conditions, such as primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy.

The report highlighted the reasoning for the drug shortage as well as specific applicants and manufacturers that the agency will be working with to mitigate the supply of Ig products.

In a Pharmacy Times Continuing Education Supplement, Elena E. Perez, MD, PhD, examined the evolution of immunoglobulin [Ig] in its treatment use, including patient populations and potential adverse events.

New approach involves treating patients with a high dose factor VIII concentrates along with emicizumab, a modification of the standard immune tolerance induction.

Specialty pharmacists play an important role in the selection of immunoglobulin G products and optimizing therapy for patients.

At the Asembia Specialty Pharmacy Summit 2019, a panel of experts educated audience members about chronic inflammatory demyelinating polyneuropathy.

Galcanezumab-gnlm (Emgality, Eli Lilly) is the first calcitonin gene-related peptide antibody approved for both migraine and episodic cluster headache in adults.

This symposium traced the evolution of immunoglobulin therapy from this inception to the state-of-the-art intravenous immunoglobulin products currently employed to manage a wide range of immune disorders.

Hizentra may treat patients with chronic inflammatory demyelinating polyneuropathy.